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Abstract
Background: The usual treatments for pleural malignancies are mostly palliative. In contrast, peritoneal
malignancies are often treated with a curative intent by cytoreductive surgery and intraperitoneal chemotherapy.
As pressure has been shown to increase antitumor efficacy, we applied the concept of high-pressure intracavitary
chemotherapy to the pleural space in a swine model.
Methods: Cisplatin and gemcitabine were selected because of their antineoplasic efficacy in vitro in a wide
spectrum of cancer cell lines. The pleural cavity of 21 pigs was filled with saline solution; haemodynamic and
respiratory parameters were monitored. The pressure was increased to 15-25 cm H2O. This treatment was
associated with pneumonectomy in 6 pigs. Five pigs were treated with chemotherapy under pressure.
Results: The combination of gemcitabine (100 mg/l) and cisplatin (30 mg/l) was highly cytotoxic in vitro. The
maximum tolerated pressure was 20 cm H20, due to haemodynamic failure. Pneumonectomy was not tolerated,
either before or after pleural infusion. Five pigs survived intrapleural chemotherapy associating gemcitabine and
cisplatin with 20 cm H2O pressure for 60 min.
Conclusions: High-pressure intrapleural chemotherapy is feasible in pigs. Further experiments will establish the
pharmacokinetics and determine whether the benefit already shown in the peritoneum is also obtained in the
pleura.
Keywords: intrapleural intracavitary chemotherapy, pressure, pig model
Background
Malignant pleural effusion is a common evolution of
many cancers, including breast, lung or ovarian cancer.
Today pleural mesothelioma is more frequent due to
occupational exposure to asbestos [1]. Whereas perito-
neal carcinomatosis may be treated by cytoreductive
surgery followed by intraperitoneal chemotherapy with
curative intent, the treatment of malignant pleural effu-
sion is generally purely palliative [2,3]. Chemical or phy-
sical pleural abrasion, pleurodesis with sclerosing agents
or talc are palliative treatments usually administered
with concomitant systemic chemotherapy. Their objec-
tive is to alleviate the dyspnea but not to sterilize the
pleural tumor [4]. As the pleura has the same histology
as the peritoneum, we hypothesized that isolated pleural
carcinomatosis could sometimes be treated with curative
intent, as for the peritoneum, through the surgical resec-
tion of macroscopic malignant tissue associated with
optimal intrapleural chemotherapy. Furthermore, this
treatment may enhance local control of malignant
pleural effusion. The major mechanism of failure for
intracavitary chemotherapy is poor drug penetration
into the depth of the tumor nodules and contaminated
serous tissue [5]. We recently proposed increasing infu-
sion pressure in the abdomen in order to enhance diffu-
sion of the anticancer drug into the peritoneum [6]. The
aim of the present study was to assess the set-up and
the feasibility of high-pressure intrapleural chemother-
apy for the treatment of pleural malignancies using a
pig model. Due to their wide antitumor spectrum
demonstrated by in vitro tests, we selected gemcitabine
and cisplatin, and evaluated tolerance to this* Correspondence: olivier.facy@chu-dijon.fr
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combination of drugs when used for high-pressure
intrapleural chemotherapy.
Methods
In vitro cytotoxicity assay
The antitumor activity of cisplatin and gemcitabine
against human breast (T47, MCF7), lung (H348,
H1650), colon (SW480, HCT116) and ovarian
(OVCAR3, IGROV1) cancer cell lines was evaluated
according to a quantitative clonogenic assay in order to
choose the drug and the doses for further in vivo
experiments [7]. The target was to kill at least 80% of
these human cancer cells after a 60 min of in vitro
treatment. Cells were obtained from ATCC (Rockville,
MD) except for IGROV1 cells, which were a gift from
Dr J. Benard [8]. Briefly, cancer cells were seeded at low
density (50 × 104/well) in 24-well tissue culture plates
for 48 hours before 60 minutes of exposure to the
drugs. The cells were cultivated again in a drug-free cul-
ture medium for 7 days. Surviving adherent cells were
fixed with pure ethanol and stained with 1% crystal vio-
let. After washing with water and dye elution with 33%
acetic acid, the optical density (OD) was read at 550 nm
on a spectrophotometer. Survival was calculated as the
OD in treated wells compared with that in untreated
control wells.
Animals
Before the experiment, 21 3-month-old large white
female pigs, weighing 50-60 kg were allowed to acclima-
tize to the laboratory environment for 7 days with free
access to standard food and water. The Animal Ethics
Committee of the University of Burgundy, France
approved the experiments (A0809).
Anesthesia
Anesthesia was induced by intramuscular injection of 1
g ketamine + 1 mg atropine then completed with intra-
venous ketamine and sufentanil until the endotracheal
intubation, without selective bronchic intubation. The
animals were maintained under anesthesia by isoflurane
(1.5%), intravenous sufentanil and cisatracurium. The
tidal volume was maintained between 500 and 600 ml
with a frequency of 25/min, adapted to the oxygen
blood saturation. The bladder was catheterized to mea-
sure urine output. Systolic systemic arterial blood pres-
sure (SAP) was monitored through a catheter inserted
into the brachial artery. The heart rate (HR), electrocar-
diogram, nasal temperature, oxygen blood saturation
(OS), cardiac output (CO in l/min) and cardiac index
(CI in l/min/m2) were measured using the NICO system
(Novametrix Medical Systems Inc., Wallingford, CT).
Antibioprophylaxis with 2 g. of amoxicilline + clavulanic
acid was given before the incision. Fluid resuscitation
was achieved with isotonic saline, Ringer lactate and
gelatine solution (Plasmion, Fresenius Kabi France,
Sèvres, France) according to cardiologic ultrasonography
parameters. No vasoactive drugs were used. Tramadol
and paracetamol were prescribed for postoperative
analgesia.
Surgery
The anesthetized pigs were placed in the supine posi-
tion. Two pleural catheters (Pleurocath®, Prodimed,
Plessis-Bouchard, France), one for infusion and one for
pressure recording, were inserted into the pleural cavity
through the 5th intercostal space. Saline solution was
perfused by gravity in increasing steps until haemody-
namic or respiratory intolerance was achieved. Six pigs
underwent right pneumonectomy either before or after
the pleural infusion. Right thoracotomy was performed
in the 5th intercostal space with the animals lying in left
lateral decubitus. The accessory bronchial branch to the
right superior lobe, always present in pigs, was ligated.
The right bronchial branch, the pulmonary vein and
artery were then ligated and pneumonectomy was per-
formed including the accessory inferior lobe. The thor-
acic wound was closed on a pleural catheter if post-
operative infusion was scheduled. Surviving animals had
a daily visit and were kept in licensed animal facilities
for 30 postoperative days until they were killed with
Dolethal® (Vetoquinol, France) and autopsied. Biological
parameters (blood cell count, and serum levels of
sodium, potassium and creatinine) were recorded before
and after the surgery, and then on postoperative days 3,
7, 14 and 28.
Anticancer drugs
Cisplatin (Sigma-Aldrich, L’Isle d’Abeau, France) and
gemcitabine (Lilly, Suresnes, France) were diluted in iso-
tonic saline solution (9 g/l NaCl) at 100 mg/l and 30
mg/l respectively and warmed to 37°C.
Drug assay
Systemic blood and pleural liquid were sampled in five
pigs at 0, 10, 20, 30, 40, 50 and 60 minutes after the
beginning of the procedure. The samples were centri-
fuged and kept frozen at -20°C until the assays. The pla-
tinum concentration was measured by atomic
absorption spectrometry (AAS) using a Zeeman atomic
absorption spectrometer (Spectra-A; Varian, Les Ulis,
France). Gemcitabine and 2,2-difluoro-2-deoxyuridine
(dFdU) were assayed following the method described by
Bowen et al [9]. Briefly, the serum was separated from
whole blood samples and underwent protein precipita-
tion by methanol after the addition of internal standards
(13C and 15N isotopic gemcitabine and dFdU). Pleural
liquid samples were simply diluted in distilled water.
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These serum and pleural samples were then derivatized
with dansyl chloride, and dansyl-derivatives were
extracted with methyl tertiary-butyl ether, evaporated
and dissolved in a mixture of acetonitril and water (25/
75). The samples were then assayed using high perfor-
mance liquid chromatography (HPLC) coupled with
Thermo Scientific tandem mass spectrometry. Chroma-
tographic separation was performed using an Atlantis®
column (3 μm, 100 × 2.1 mm - Waters, USA) and the
transitions used were 497.0 ® 111.9, 500.0 ® 114.9,
498.1 ® 236.9 and 501.0 ® 115.8 for the dansyl-deriva-
tives of gemcitabine, isotopic gemcitabine, dFdU and
isotopic dFdU, respectively. This method yielded a
quantification limit of 0.010 μg/ml and was linear over
the range of the concentrations studied.
Results
Tolerance to intrapleural pressure
Two pigs (animals 1 and 2) underwent percutaneous
pleural infusion into the left thorax. At a pressure of
about 15 cm H2O (11.5 mmHg), the mediastinal pleura
broke in both pigs and the filled right pleural cavity was
confirmed by ultrasonography and autopsy. Intrapleural
pressure could not be maintained, haemodynamic para-
meters (systemic arterial pressure, cardiac output) failed
and the animals died. Due to this fragility of the med-
iastinal pleura in the pig, further experiments were
always performed on the right pleura (table 1).
Two pigs underwent a percutaneous procedure in the
right thorax (animals 3 and 4). A pressure of 15 cm
H2O was well tolerated for 30 minutes, with slight hae-
modynamic modifications (SAP showed a 15% decrease,
HR increased by 25%, OS and CO decreased by 10%). A
sustained pressure of 20 cm H2O (15.4 mmHg) on the
pleura was obtained for 30 min or 60 min in 3 other
animals (5, 6 and 7). This pressure was obtained in 1
hour by pleural filling with 4 l of isotonic saline solu-
tion. However, the fall in the systemic arterial pressure
and cardiac output made it necessary to slow down the
pleural inflow, mainly when a pleural pressure of 15 to
20 cm H2O was reached. The slow infusion of a mean
of 500 ml of additional saline was required to maintain
pleural pressure at 20 cm H2O. At this time of the pro-
cedure, the peak inspiratory pressure reached 45 cm
H2O. Increasing pleural pressure to 25 cm H2O (20
mmHg) was tested in three animals (8, 9 and 10), but
resulted in a decrease in systemic arterial pressure to
below 40 mm Hg, and in the cardiac index to below 1.5
l/m2/min (table 2). Haemodynamic instability was asso-
ciated with ECG signs of ischemia. In one animal, hae-
modynamic failure was reversible after emptying the
pleural cavity but two other pigs died despite emptying,
fluid resuscitation and cardiac massage.
Pleural pressure was then combined with pneumo-
nectomy corresponding to the treatment of mesothe-
lioma. Three pigs had lung resection followed by pleural
Table 1 Synthesis of methods and results of all animals treated.
Pig Side Pneumonectomy Chemotherapy Pressure (cmH20)/time (min) Outcomes
1
2
Left No No 15/5 Left to right pleural filling
3
4
Right No No 15/30 Well tolerated
5
6
Right No No 20/30 Moderate haemodynamic changes
7 Right No No 20/60
8 Right No No 25/5 Major but reversible haemodynamic instability
9
10
Right No No 25/5 Peroperative death
11 Right 15/15 Controlateral breach
12 Before infusion No 20/5 Peroperative death
13 15/15 Major but reversible haemodynamic instability
Postoperative death
14
15
16
Right After infusion No 20/40 Moderate haemodynamic changes
Postoperative death
17
18
19
20
21
Right No Cisplatin
(30 mg/l)
Gemcitabin
(100 mg/l)
20/60 Moderate haemodynamic changes
No morbidity
Pleurodesis
Moderate haemodynamic changes are defined as a decrease in arterial pressure and cardiac output requiring vascular resuscitation. When haemodynamic
modifications persisted, they were major, and reversible if emptying saved the animal, or lethal if not.
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infusion (11, 12 and 13). Severe haemodynamic, electric
and ultrasonographic alterations occurred with 15 cm
H2O pleural pressure. The first pig presented right to
left filling and died. The second pig also died when we
attempted to increase the pressure to 20 cm H20. The
third animal survived the operation (but the infusion
had to be shortened to 15 minutes at a pressure of 15
cm H2O), but died on the first post-operative day.
Three animals had the reverse sequence, with the
pleural infusion first, and then the right lung resection
(14, 15 and 16). An intrapleural pressure of 20 cm H2O
was easily tolerated for 30 minutes after filling with a
mean of 4 l of saline solution infused in dorsal decubi-
tus. After emptying the pleura, the animals were placed
on their left sides and pneumonectomy was performed.
Despite immediate survival, the 3 animals died on the
first post-operative day.
Selection of an active combination of drugs
Gemcitabine and cisplatin were tested alone or in com-
bination with the target to kill at least 80% of various
human cancer cells after 60 minutes of in vitro treat-
ment (Figure 1). The objective was achieved with a com-
bination of 100 mg/l gemcitabine and 30 mg/ml
cisplatine for lung (H458, H1650) and breast (T47,
MCF7) cancer cells but not for colon cancer cells
(SW480, HCT116). Both ovarian cancer cell lines
(OVCAR3 and IGROV1) were extremely sensitive to
both drugs.
Tolerance to intrapleural chemotherapy with pressure
Intrapleural hyperpressure chemotherapy combining 30
mg/l cisplatin and 100 mg/l gemcitabine for 60 min was
finally performed in 5 animals (17, 18, 19, 20 and 21).
The intrapleural chemotherapy was well tolerated. A
pressure of 20 cm H2O was maintained for 40 (animal
17) or 60 min (animals 18, 19, 20 and 21). All of the
animals survived with a normal clinical status, as well as
normal blood cell count, creatinine and ionogram dur-
ing the first month. At autopsy, tight pleurodesis was
observed, and pathological examination of pulmonary
samples showed a normal parenchyma. Pharmacokinetic
analysis showed a stable pleural concentration of cispla-
tin throughout the infusion with a low systemic concen-
tration. In the same way, constant high levels of
gemcitabine were achieved in the pleural cavity. Almost
no gemcitabine was metabolized to dFdU. Systemic
levels of both drugs were very low, less than 0.1% of the
pleural infusion.
Discussion
Intrapleural chemotherapy has been used for a long time
to treat malignant pleural effusion, but its efficacy is
poor [10-15]. Some physical parameters, like hyperther-
mia, which is usually associated with intraperitoneal
chemotherapy, are used to enhance drug uptake in can-
cer cells and cytotoxicity [13,14]. We previously demon-
strated that increasing the abdominal pressure by filling
the closed abdominal cavity resulted in the increased
penetration of cisplatin into peritoneal tumor nodules
and enhanced its antitumor activity in a murine model
[6,16]. One of the known limits of anticancer drugs in
intracavitary treatment is their poor penetration into tis-
sues [5,17], due to the peritoneal barrier, which is histo-
logically the same as the pleural barrier [18,19].
Extrinsic pressure could counterbalance the interstitial
pressure, which is high in solid tumors (18 cm H2O in
breast cancer, 27 cm H2O in cervical cancer, 23 to 41
cm H2O for head and neck cancer, 47 cm H2O in renal
cancer, and 7 to 37 cm H2O in melanoma xenografts)
[20]. Moreover, increased pressure in the cavities coun-
teracts the hydraulic capillary pressure, which limits the
diffusion of anticancer drugs from the cavity into tumor
nodules. A pressure of 50 cm H2O (40 mm Hg) can
easily be achieved for 2 hr in the abdomen of ventilated
pigs after an average infusion of 8 l saline solution [6].
In non-ventilated rats, an abdominal pressure of only 26
cm H2O (22 mm Hg) was achievable after infusion of
an average of 120 ml in 300-350 g animals. Neverthe-
less, this low level of pressure resulted in a 3-fold
Table 2 Mean and standard deviations of haemodynamic and respiratory parameters before (0 mmHg) and during
infusion (15, 20 and 25 mmHg).
Intrapleural
pressure
Heart Rate
(/min)
Systolic Systemic Arterial
Pressure
(mmHg)
Cardiac
Output
(l/min)
Oxygen Saturation
(%)
Ventilation pressure (cm
H2O)
0 cm H2O 99.2
+/- 10.9
69.7
+/- 10.9
7.1
+/- 1
98.9
+/- 0.9
27.7
+/- 4.1
15 cm H2O 124.5
+/- 5.6
59.8
+/- 9.3
6.3
+/- 0.9
90.1
+/- 0.7
35
+/- 3.2
20 cm H2O 140.3
+/- 8.9
48.9
+/- 8.5
4.8
+/- 0.7
90.3
+/- 1
45.2
+/- 2.8
25 cm H2O 158
+/- 7.3
40.2
+/- 4.5
2.8
+/- 0.6
86.2
+/- 2.3
49.8
+/- 3.8
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increase in platinum concentration in the tumour
nodules compared with the same administration without
hyperpressure. As a consequence, rats bearing milli-
metric peritoneal carcinomatosis were cured after
intraperitoneal cispatin chemotherapy with pressure
whereas rats which received conventional intraperitoneal
injections were not [6]. This prompted us to assess the
feasibility of pleural infusion with hyperpressure.
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Figure 1 In vitro assay of 15 mg/l (CP 15) and 30 mg/l cisplatin (CP 30) and 50 mg/l (GEM 50) and 100 mg/l gemcitabine (GEM 100)
on human colon, breast, lung and ovarian cancer cells. Cell survival was analyzed 7 days after 60 minutes of exposure to the drug or their
association.
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Intrapleural pressure is more difficult to achieve than
abdominal pressure in pigs. In the present study, a pres-
sure of 25 cm H20 could not be reached in the right
pleura of ventilated pigs. A lower level (20 cm H20) was
well tolerated for up to 1 hr. The inspiratory plateau
pressure, necessarily lower than 35 cm H2O, was not
measurable in our ventilation machine [21]. Neverthe-
less, the clinical tolerance was good despite a high peak
inspiratory pressure. Performing lung biopsies at the
end of the procedure and monitoring of ventilatory
parameters (like plateau pressure) may increase the
safety of this approach. A pressure of 20 cm H2O was
sufficient to at least double the concentration of plati-
num in peritoneal tumour nodules in rats (unpublished
data). Pleural filling had to be slow (average 1 hour for
4 l). Monitoring of the pleural pressure made it possible
to adapt filling to haemodynamic changes which
appeared above 15 cm H20. Vascular filling was modi-
fied according to cardiac ultrasonography monitoring. In
the case of major haemodynamic failure, quick pleural
emptying made it possible to reverse the situation. Fac-
tors which limit pleural pressure appear to be related
more to mediastinal compression (heart, aorta, vena
cava) than to the controlateral lung compression. Poor
tolerance to increased pressure in the pleural compart-
ment is well known, whatever the cause (tension pneu-
mothorax or liquid effusion). This is more related to
haemodynamics than to oxygenation disturbances
[22,23]. In our experience, the first two parameters that
dropped were cardiac output and systemic arterial pres-
sure, before the fall in blood oxygen saturation. We
think that the best ways to enhance tolerance to this
procedure are slow infusion and efficient vascular filling.
These appear better than decreasing tidal volume and
increasing ventilation frequency.
Despite the well-known similarities to humans in
terms of anatomy and physiology, the pig model has
some drawbacks. Like humans, pigs have two separate
pleural cavities, while rats have a single pleural space.
However the mediastinal separation is thin and fragile
in the pig. As a consequence, filling the left pleura twice
resulted in fluid leakage to the right through a mediast-
inal breach, which occurred at a pressure of only 15 cm
H2O. In contrast, filling the right pleura did not result
in pleural breach. This is probably due to a protective
effect of the median inferior lobe in the right pleural
space. In humans, the separation between the right and
left pleural compartments is thicker and the risk of leak-
age is probably similar after left or right infusion, given
that any difference between the left or right pleura is
not typical in clinical conditions, like hypertensive pneu-
mothorax [23]. The second drawback is the poor toler-
ance of pigs to pneumonectomy, which is consistent
with the findings of other authors [24]. Moreover the
thin mediastinal pleura must be carefully protected dur-
ing right lung resection because of the risk of injury and
leakage. In addition, haemodynamic tolerance to pleural
filling was poor (15 cm H2O was barely tolerated) when
previous pneumonectomy had been performed. In con-
trast, initial pleural filling followed by pneumonectomy
was tolerated just as well as in animals without lung
resection. This is a major limit of the pig model for the
preclinical evaluation of high-pressure intrapleural che-
motherapy and lung resection as a treatment for
mesothelioma. The thin mediastinal pleura and the poor
tolerance to pneumonectomy explain the high mortality
rate of our intrapleural chemotherapy setup (10/21).
Nevertheless, all of the animals that underwent high-
pressure intrapleural chemotherapy without lung resec-
tion survived the procedure. Another limitation is the
lack of a model of pleural carcinomatosis in the pig,
which could be used to evaluate the antitumor effect of
high-pressure intrapleural chemotherapy. Models of
malignant pleural effusion exist in rats, but rats have a
single pleural space thus precluding high-pressure
pleural infusion [15]. This experimental model is based
on the similarities between the peritoneum and pleura,
but the interest of high-pressure to increase the penetra-
tion of chemotherapy in pleura has to be proved is
further studies, with tissue samples in the same way as
in peritoneal studies [25].
Chemotherapy associating cisplatin and gemcitabine
was well tolerated when diluted in 4 l of saline solution
and maintained for 40 to 60 min in the right pleural
cavity under a constant pressure of 20 cm H20. In this
study, we selected cisplatin and gemcitabine for their
rapid cytotoxic effect against a variety of human cell
lines originating from cancers that frequently affect the
pleura. Moreover, the cisplatin/gemcitabine combination
is synergistic on lung cancer and mesothelioma [26,27].
We used 30 mg/l (120 mg for 4 l) cisplatin and 100 mg/
l (400 mg for 4 l) gemcitabine for intrapleural che-
motherapy in 50-60 kg pigs. These total doses are in the
range of those used for intravenous administration in
patients (i.e. 120 mg cisplatin and 1500 mg gemcitabine
for a 60-kg patient treated for lung cancer). The meta-
bolism of gemcitabine to inactive dFdU was negligible in
the pleura, but greater in the blood (on average 30%).
As a consequence of this low systemic diffusion, no
intra-operative changes were recorded in chemotherapy-
treated animals as compared to those which received
drug-free saline in the pleural space. This low systemic
diffusion is also of interest with regard to the absence of
potential toxicity. Animals did well during the operation
and until the autopsy 1 month later, without neurologi-
cal, haematological, or renal toxicity. The pleural adher-
ences seen at the autopsy could be an advantage as they
ensure solid pleurodesis and reduce the risk of recurrent
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pleural effusion. Five pigs were necessary for this toler-
ance study given the good peri-operative tolerance of
the drug-free filling group (3 pigs for the 20 cmH2O
level of pressure). Future studies to establish the phar-
macokinetics of high-pressure intrapleural chemotherapy
precisely (both in the blood and the tissue) at different
levels of pressure will contribute to the next step of this
research program.
Conclusion
This feasibility study reports for the first time the con-
cept of high-pressure intrapleural chemotherapy. In pigs,
this technique using cisplatin and gemcitabine was well
tolerated in the absence of pneumonectomy at 20
cmH2O. Given the similarity between the pleura and
peritoneum, high-pressure could enhance the penetra-
tion of drugs with minimal systemic diffusion, but this
needs to be assessed in further experiments.
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